Insight stories
Continuous Innovation: How GEA is Leading the Future of Pharmaceutical Manufacturing
From the first ConsiGma® line in 2004 to the launch of CDC Flex today, GEA has been at the forefront of pharmaceutical innovation.
Continuous innovation is our commitment — to our customers, to the industry, and to a better world.
現在と将来の医薬製造
癌などの疾病のゲノム基盤を科学者が解明するにつれて、同じ症状に対してさまざまな薬物を開発し、特定の遺伝子プロファイルを有する患者を標的にすることがますます可能になっています。 これは比較的少量で必要になる個別化薬物療法のための薬物を製造する必要性を引き起こすだけでなく、当該薬物生産に関わる製造技術はより柔軟性のあるものであることが求められ、さまざまな製剤生産と特殊製品生産の切り替えにも素早く対応できる必要があります。 究極の目的は、世界の誰もが最も有効な医薬品にアクセスできるように、より安全な医薬品をより効率的でコスト効果的な方法で市場に投入して地元で利用可能にすることです。
How continuous manufacturing is redefining the pharmaceutical supply chain
Continuous pharmaceutical manufacturing is no longer a niche trend. It’s already happening. Although implementation and knowledge transfer can be time consuming, early adopters are embarking on a new trajectory of business excellence, benefiting from numerous competitive advantages and staying ahead of the market.
The unsung heroes of global health and well-being
When we consider the concept of health, we generally think about being free from injury or illness. We might look at a person’s mental or physical condition, or delve more deeply into nutrition, exercise, sleep and the environment we live in. In recent times, vaccines and medicines have taken center stage as the world battles the ongoing pandemic. Yet, often behind the scenes and anonymous, a vast array of technologies and innovations are working hard, every day, to ensure that the food, drugs, water and energy that we use to stay well are safe, reliable and sustainable. At the heart of many of those processes – and supporting healthy living – is GEA equipment.
